MeSH D012595 - systemic scleroderma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Actelion | Epoprostenol | Veletri | 2027-02-02 | 2008-06-27 |  |  |
| GSK | Epoprostenol | Flolan |  | 1995-09-20 |  |  |
| Johnson & Johnson | Bosentan | Tracleer |  | 2002-05-14 | $341 M | Y2019 |
| Meitheal Pharmaceuticals | Epoprostenol | Epoprostenol |  | 2008-04-23 |  |  |
| Mylan | Epoprostenol | Epoprostenol |  | 2024-06-12 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
78%36/46
Phase 2
32%22/69
Phase 3
17%6/36
Approved: 4Overall Success rate: 4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use